Pediatric Pyelonephritis Treatment & Management

  • Author: Robert W Tolan Jr, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Feb 9, 2012
 

Approach Considerations

Routine supportive care in pyelonephritis includes adequate hydration, analgesia, and the use of antipyretics. IV fluid replacement and parenteral antibiotics are indicated for children unable to take medication and fluids orally. IV therapy may be continued until the child can receive oral medication and fluids. Septic or toxic patients require hospitalization for treatment.

Treatment with fluids and oral antibiotics may be given on an outpatient basis if children are not vomiting and not markedly ill.

The optimal duration of therapy is not well studied, although recommended treatment is in the range of 7-14 days. Some studies have shown that recurrent infection rates increase with short courses of treatment.

Deterrence and prevention

A study noted that in children with or without primary nonsevere reflux, prophylaxis does not reduce the rate of recurrent febrile UTIs after the first episode and thus is no longer recommended.[14]

Consultations

Consultations are typically not required at the time of presentation. A urologist should be consulted for an infant or child with obstruction or a clinically significant anomaly of the urinary tract. Consultation with an infectious diseases specialist is necessary only if an unusual or resistant organism is identified. Consult a nephrologist when patients have impaired renal function.

Next

Antibiotic Therapy

The results of urine cultures ultimately dictate the choice of antibiotics.[15] Because E coli causes more than 95% of all cases of acute pyelonephritis in children, initial treatment should be based on regional susceptibility to this pathogen. Because of high resistance rates to amoxicillin, initial treatment should include a cephalosporin, amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole (TMP-SMZ), or aminoglycoside.[16, 17, 18]

Initial therapy with IV antibiotics for 3-4 days followed by oral therapy to complete a 10-14 day course is equivalent to 10-14 days of IV therapy.

Initial oral therapy with cefixime or amoxicillin-clavulanate is equivalent to IV ceftriaxone for 3 days followed by oral therapy. Rates of renal scarring are equal in children treated orally or intravenously, although further study is needed to determine whether a subgroup of children with dilating VUR may have high rates of renal scarring if treated with oral antibiotics. Further studies are needed to ensure that currently available antibiotics have the same efficacy. The results of one study noted that children with a high risk of renal scar formation realized a reduced occurrence and/or severity of renal scarring with antibiotic therapy combined with oral methylprednisolone sodium phosphate (1.6 mg/kg/d for 3 d).[19]

A single dose of ceftriaxone given intramuscularly (IM) followed by oral therapy offers no advantage over 10 days of oral therapy alone. Hospitalization is required in similar numbers because of vomiting.

IV gentamicin may be dosed daily, rather than 3 times a day, for children who require IV treatment or who are infected with multiresistant organisms.

Previous
Next

Inpatient Care

Hospitalization is necessary for pyelonephritis in any of the following situations:

  • Toxicity or sepsis
  • Signs of urinary obstruction or significant underlying disease
  • Inability to tolerate adequate oral fluids or medications
  • Infants and children younger than age 2 years with febrile UTI, presumed pyelonephritis
  • All infants younger than age 3 months
Previous
Next

Outpatient Care

Patients treated exclusively in the outpatient setting should be reevaluated in 48 hours to ensure adequate hydration and an appropriate response to therapy. For a first infection, perform renal ultrasonography.Manage constipation and voiding dysfunction.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: Novartis Honoraria Speaking and teaching

Coauthor(s)

Stephen C Aronoff, MD  Waldo E Nelson Chair and Professor, Department of Pediatrics, Temple University School of Medicine

Stephen C Aronoff, MD is a member of the following medical societies: Pediatric Infectious Diseases Society and Society for Pediatric Research

Disclosure: Nothing to disclose.

Andrea CS McCoy, MD  Associate Professor of Pediatrics, Temple University School of Medicine; Chief Medical Officer, Jeanes Hospital

Andrea CS McCoy, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Montini G, Tullus K, Hewitt I. Febrile urinary tract infections in children. N Engl J Med. Jul 21 2011;365(3):239-50. [Medline].

  2. Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. Pediatrics. Dec 2010;126(6):1084-91. [Medline].

  3. Lundstedt AC, Leijonhufvud I, Ragnarsdottir B, et al. Inherited susceptibility to acute pyelonephritis: a family study of urinary tract infection. J Infect Dis. Apr 15 2007;195(8):1227-34. [Medline].

  4. Faust WC, Diaz M, Pohl HG. Incidence of post-pyelonephritic renal scarring: a meta-analysis of the dimercapto-succinic acid literature. J Urol. Jan 2009;181(1):290-7; discussion 297-8. [Medline].

  5. Bhat RG, Katy TA, Place FC. Pediatric urinary tract infections. Emerg Med Clin North Am. Aug 2011;29(3):637-53. [Medline].

  6. Williams GJ, Macaskill P, Chan SF, Turner RM, Hodson E, Craig JC. Absolute and relative accuracy of rapid urine tests for urinary tract infection in children: a meta-analysis. Lancet Infect Dis. Apr 2010;10(4):240-50. [Medline].

  7. Pecile P, Romanello C. Procalcitonin and pyelonephritis in children. Curr Opin Infect Dis. Feb 2007;20(1):83-7. [Medline].

  8. American Academy of Pediatrics. Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. Pediatrics. Aug 28 2011;[Medline].

  9. Wang YT, Chiu NT, Chen MJ, et al. Correlation of renal ultrasonographic findings with inflammatory volume from dimercaptosuccinic acid renal scans in children with acute pyelonephritis. J Urol. Jan 2005;173(1):190-4; discussion 194. [Medline].

  10. [Guideline] Subcommittee on Urinary Tract Infection; Steering Committe on Quality Improvement and Management. Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. Pediatrics. Aug 28 2011;[Medline].

  11. Lee YJ, Lee JH, Park YS. Risk Factors for Renal Scar Formation in Infants With First Episode of Acute Pyelonephritis: A Prospective Clinical Study. J Urol. Jan 18 2012;[Medline].

  12. Kovanlikaya A, Okkay N, Cakmakci H, et al. Comparison of MRI and renal cortical scintigraphy findings in childhood acute pyelonephritis: preliminary experience. Eur J Radiol. Jan 2004;49(1):76-80. [Medline].

  13. Kavanagh EC, Ryan S, Awan A, et al. Can MRI replace DMSA in the detection of renal parenchymal defects in children with urinary tract infections?. Pediatr Radiol. Mar 2005;35(3):275-81. [Medline].

  14. Montini G, Rigon L, Zucchetta P, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics. Nov 2008;122(5):1064-71. [Medline].

  15. Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. Oct 17 2007;CD003772. [Medline].

  16. Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev. Jul 19 2006;3:CD001534. [Medline].

  17. Garin EH, Olavarria F, Garcia Nieto V, et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics. Mar 2006;117(3):626-32. [Medline].

  18. Bloomfield P, Hodson EM, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. Jan 25 2005;CD003772. [Medline].

  19. Huang YY, Chen MJ, Chiu NT, Chou HH, Lin KY, Chiou YY. Adjunctive Oral Methylprednisolone in Pediatric Acute Pyelonephritis Alleviates Renal Scarring. Pediatrics. Aug 15 2011;[Medline].

Previous
Next
 
Application of low-risk criteria and approach for the febrile infant: A reasonable approach for treating febrile infants younger than 3 months who have a temperature of greater than 38°C.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.